When it comes to biotech investing, the value opportunities in Australia attract many of the world’s smartest investors. Amongst them, Platinum Asset Management (ASX: PTM) has joined a growing list of institutions taking a substantial stake in a little-known Aussie biotech set to announce hugely-anticipated clinical trial results within the next few months. With more
Read More
More than 100,000 people in Australia live with Parkinson’s—a central nervous system disorder affecting one’s movement and mood. It is a progressive disorder which currently has no cure and few treatments. However, researchers at Parkinson’s UK have a new reason to hope. They are investigating whether early detection and treatment of certain sleeping disorders might
Read More
For patients given less than five years to live after being diagnosed with myelofibrosis, there is a new flicker of hope after clinical stage drug development company Pharmaxis (ASX: PXS) reported encouraging interim data from their Phase 2 trials. Myelofibrosis is a rare cancer of the bone marrow affecting 15 per 1 million people worldwide.
Read More
This morning’s announcement may have surprised many investors following the Pharmaxis (ASX: PXS) story because where on earth does Parkinson’s fit into the equation alongside cancer, skin scarring and cystic fibrosis? Unpacking the Pharmaxis investment case reveals an agile company with more than one trick up their sleeves, keeping business buoyant whilst other biotechs list
Read More
Aptar Pharma has deemed now the perfect time to exercise their option to purchase an inventive piece of Pharmaxis’ (ASX: PXS) technology. In August, 2021 Aptar signed an exclusive option agreement to Pharmaxis’ “Orbital” technology, handing over USD $250,000. Now, a little under a year later, Aptar is deploying USD $2.5 million to exercise the
Read More